Record: 21

01/17/2020

Daily Note

Pages: 3

Dropping Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Record: 22

12/30/2019

Company Report

Pages: 4

Financing Completed; Runway Lengthened; Reducing Target to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 23

12/11/2019

Company Report

Pages: 4

VIITAL Pivotal Trial Program Cleared to Proceed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 24

11/20/2019

Company Report

Pages: 5

Awaiting Final Pivotal Program Clearance; 3Q19 Financials Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 25

10/16/2019

Company Report

Pages: 5

Positive Long-Term EB-101 Data Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 26

08/12/2019

Company Report

Pages: 5

2Q19 Financial Results Reported; EB-101 Pivotal Trial Initiation Approaching; Lowering Target to $15 Ahead of Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 27

07/29/2019

Company Report

Pages: 5

ABO-102 Interim Data Appear Positive; EB-101 Pivotal Program Timeline Updated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 28

06/19/2019

Company Report

Pages: 4

ABO-202 Fast Track Designation Granted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 29

05/28/2019

Company Report

Pages: 5

Gene Therapy Pricing Paradigm Emerges; EB-101 Program Continues Progress; Reiterate Buy; Modulating Target to $23

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 30

05/06/2019

Company Report

Pages: 4

Retinal Disease Therapeutic Potential Showcased at ARVO Meeting; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 31

05/01/2019

Company Report

Pages: 4

New Preclinical Data Herald Potential in Cystic Fibrosis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 32

04/15/2019

Company Report

Pages: 4

ABO-101 Fast Track Designation Received; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 33

03/25/2019

Company Report

Pages: 4

Brammer Bio Acquisition Underscores Gene Therapy Strategic Interest; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 34

03/20/2019

Company Report

Pages: 4

2018 Financial Results Reported; Multiple Clinical Catalysts Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 35

02/28/2019

Company Report

Pages: 4

M-A Rife in Gene Therapy Sector; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 36

02/21/2019

Company Report

Pages: 4

Permanent Chief Executive Appointment; New Supportive Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 37

12/07/2018

Company Report

Pages: 5

R-D Day Highlights Pipeline Depth; EB-101 Entering Pivotal Testing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 38

09/21/2018

Company Report

Pages: 5

Celenex Acquisition Underscores Gene Therapy Asset Value; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 39

09/13/2018

Company Report

Pages: 4

Authorization Granted for European Enrollment Initiation in Sanfilippo Syndrome Type B; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Record: 40

08/13/2018

Company Report

Pages: 4

2Q 2018 Financial Results Reported; Multiple Clinical Development Milestones Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00